logo
Tradeweb Introduces T-bill Trading on ICD Portal

Tradeweb Introduces T-bill Trading on ICD Portal

Business Wire26-06-2025
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities, and money markets, today announced the launch of direct U.S. Treasury bill (T-bill) trading for corporate treasurers via direct connection between its ICD Portal and its institutional trading platform.
The launch of T-bills is an important first step toward integrating corporate treasurer workflows across a variety of Tradeweb products, geographies, and liquidity pools in the future.
Corporate treasurers using ICD Portal can now trade T-bills through Tradeweb's institutional trading platform, allowing them to manage T-bill investments seamlessly alongside other core investment options on ICD Portal—including money market funds, separately managed accounts, bank deposits, and bond funds—through a single, integrated solution.
Tradeweb, a global leader in electronic trading, acquired Institutional Cash Distributors ('ICD') in 2024 to establish a dedicated client vertical for corporate treasury, delivering a comprehensive, end-to-end solution for managing global corporate liquidity, trading, and investment operations.
The launch of T-bills is an important first step toward integrating corporate treasurer workflows across a variety of Tradeweb products, geographies, and liquidity pools in the future—beginning with trade execution and straight-through processing on highly liquid products and currencies. Tradeweb will collaborate closely with corporate clients to find the most innovative and useful ways for them to transfer risk and optimize cash.
Tory Hazard, Managing Director, ICD, said: 'Tradeweb is uniquely positioned to provide corporate treasurers with a comprehensive and efficient trading experience. The direct T-bill trading capability on ICD Portal—combined with our advanced price discovery and order execution technologies—offers corporate clients a powerful, automated workflow that enhances cash management, minimizes risk, and supports optimal liquidity. This launch reflects our commitment to leveraging our institutional platform to deliver the fixed income products in highest demand by corporate treasury teams. We plan to add more fixed income instruments to ICD Portal in the future, aligning with our clients' evolving investment strategies.'
Today, ICD Portal facilitates more than $4.5 trillion in annual trading volume and is one of the largest U.S. institutional investment portals. It enables 550+ corporate treasury organizations—primarily from high-growth and blue-chip companies, including approximately 17% of the S&P 100, as of December 31, 2024—to invest in money market funds and other short-term instruments to better manage liquidity. With the launch of T-bills and a growing roadmap of fixed income offerings to come, Tradeweb continues to evolve as a centralized destination for corporate investors seeking greater control, transparency, and efficiency in managing short-term investments.
About Tradeweb Markets
Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities, and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing, and reporting for more than 50 products to clients in the institutional, wholesale, retail, and corporates markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves more than 3,000 clients in more than 85 countries. On average, Tradeweb facilitated more than $2.2 trillion in notional value traded per day over the past four fiscal quarters. For more information, please go to www.Tradeweb.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading 'Risk Factors' in the documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future events or performance and future events, our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if future events, our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of events, results or developments in future periods.
Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange
MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange

Yahoo

time5 minutes ago

  • Yahoo

MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange

MEI Pharma, Inc. (NASDAQ:MEIP) is one of the . On July 18, MEI Pharma, Inc. (NASDAQ:MEIP) announced securities purchase agreements for a private investment in public equity (PIPE) for the sale and purchase of 29,239,767 shares of common stock at a price of $3.42 per share. A modern pharmaceutical laboratory with research scientists working at their desks. The expected aggregate gross proceeds for the transaction come up to approximately $100 million before the exclusion of placement agent fees and other estimated offering expenses. MEI Pharma, Inc. (NASDAQ:MEIP) has plans to use all of the net proceeds for the launch of its treasury strategy focused on Litecoin. The transaction is thus a notable milestone for the company's long-term strategic plan, establishing MEI Pharma, Inc. (NASDAQ:MEIP) as the first and only publicly traded company to adopt Litecoin as a treasury reserve asset. Often referred to as 'silver to Bitcoin's gold,' Litecoin is a peer-to-peer cryptocurrency that Charlie Lee created in October 2011. The integration of Litecoin into its treasury operations has allowed MEI Pharma, Inc. (NASDAQ:MEIP) access to a decentralized monetary asset that complements its cash management framework. MEI Pharma, Inc. (NASDAQ:MEIP) is a pharmaceutical company that develops pharmaceutical compounds. Its programs include Voruciclib and ME-344. While we acknowledge the potential of MEIP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)

Yahoo

time35 minutes ago

  • Yahoo

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)

ProKidney Corp. (NASDAQ:PROK) is one of the . On July 15, JP Morgan analyst Anupam Rama maintained a neutral stance on ProKidney Corp. (NASDAQ:PROK), giving the stock a Hold rating without a price target. A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. The analyst based the rating on the company's current developments. He acknowledged that ProKidney Corp.'s (NASDAQ:PROK) recent alignment with the FDA for an accelerated approval pathway for rilparencel is an optimistic development and highlights progress in its pivotal PROACT 1 study. However, Rama also stated that the time for the attainment of necessary data for the accelerated approval is longer than previously expected, as key data is expected to roll out in Q2 2027. The analyst thus reasoned that although there have been notable optimistic updates in the trial, the extended timeline may weigh on investor sentiment, warranting a cautious outlook on the stock. ProKidney Corp. (NASDAQ:PROK) is a clinical-stage biotechnology company that develops a proprietary cell therapy platform. The company's emphasis is on chronic kidney disease treatment, shifting focus to kidney function restoration to delay or stop the progression of CKD. While we acknowledge the potential of PROK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target

Yahoo

time35 minutes ago

  • Yahoo

H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target

Vor Biopharma Inc. (NASDAQ:VOR) is one of the . In a report released on June 30, Swayampakula Ramakanth from H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR) to a Buy with a price target of $3.00. The analyst based the optimistic outlook on the company's growth potential and strategic advancements. A scientist in a lab coat looking through a microscope at a petri dish of hematopoietic stem cells. Vor Biopharma Inc. (NASDAQ:VOR) recently announced an exclusive license agreement with RemeGen Co. for the development and commercialization of telitacicept in regions outside of Greater China. Telitacicept is a promising recombinant fusion protein and has already exhibited clinical success, attaining marketing approvals in China for a number of conditions, including generalized myasthenia gravis, systemic lupus nephritis, and rheumatoid arthritis. The analyst further reasoned that the financial structure of the agreement lends Vor Biopharma Inc. (NASDAQ:VOR) financial strength because it includes upfront payments and potential milestone payments. Vor Biopharma Inc. (NASDAQ:VOR) is a clinical-stage cell therapy company that develops cell therapies for the treatment of cancer. It combines therapies with a novel patient engineering approach to provide a single company solution for hematological malignancies. While we acknowledge the potential of VOR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store